order revenu stellar margin ep
varian report impress top-line beat beat
gross order quarter headlin result look good gross
oper margin consensu expect bp
bp lower respect go quarter
apprehens share worri tariff could hit margin push
guidanc street plan off-set tariff
impact see impress suppli chain shift
tweak still guid ep street driven
remain hit worri bit preview
revenu guidanc set street
estim yet anticip oper margin non-gaap ep
came consensu seem bp
margin impact relat china also invest
spend drive top-line growth overal see order revenu
result posit ultim earn matter feel share
trade flattish slightli afterhour wednesday
multipl product line run cylind
combo halcyon truebeam system complet
softwar offer strong grow servic focu offer
fuller patient solut within oncolog help grow bit
market rate strong revenu order continu
use multipl product option fulfil varieti custom
need win competit bid mani tender addit
revenue convers faster seemingli driven tender
spend tariff hit ep activ spend futur
growth top trade war would hit
compani plan off-set still lead
slower ep growth street model quarter also miss
consensu feel may off-set posit order revenue momentum
valuat varian rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
varian report total revenu continu oper
estim street beat
came oncolog revenu compani post gross oncolog
order street varian report proton
revenu model
quarter gross oncolog order y/i constant currenc
includ y/i america y/i constant currenc emea
y/i constant currenc apac region
gross margin bp model pressur impact
tariff sg spend percentag revenu bp estim
 spend bp lower forecast lower oper
spend off-set weak gross margin result oper margin bp
better forecast tax higher expect larg revenu
beat rel in-lin ebit margin higher tax non-gaap ep
cent forecast
actualsbtig estimate varianceoncolog revenu revenu revenu gross order gross order incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
believ recent strength gross order broad-bas increas
oncolog gross order estim across region
adjust proton gross order outlook
oncolog revenu forecast increas driven
higher report forecast order expect
faster revenu convers rate seen recent quarter continu increas
estim proport trail order convert
oncolog product revenu adjust proton revenu forecast
forecast total revenu y/i within
guidanc rang growth y/i
 reduc gross margin estim increas
spend percent revenu model non-gaap oper margin
within guidanc rang project non-
oper margin model non- tax rate
beyond chang model forecast non-gaap
ep within guidanc rang
project non-gaap ep repres compound-annual-growth-rate non-gaap
ep
varian rate neutral feel current valuat ntm
ep estim fair expens varian slight premium multipl
compani similar growth btig assign price target neutral-
rate stock risk includ halcyon adopt chang oper margin
capit spend slowdown hospit govern new
competit healthcar multipl gener trade lumpi quarterli
gross incom ebit btig estim compani filingsnewold chang
ntm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discont op non-control non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
